5:45:46 AM PDT - Monday, March 30th, 2020

Mesa Biotech gains emergency FDA approval for rapid, point-of-care COVID-19 test  

By Editor - Tue Mar 24, 6:40 am

The U.S. Food and Drug Administration (FDA) is making use of its Emergency Use Authorization (EUA) powers to expand the pool of available COVID-19 testing resources in the U.S., and now you can add another rapid test that delivers results in just 30 minutes to the list. Mesa’s test is also small enough to be able to be used right at the frontline of care, including in clinics and hospitals, with multiple tests able to be run in parallel. Mesa’s rapid test follows one from Cepheid that was approved on Monday . Both are PCR-based molecular tests, which identify the presence of virus DNA in a sample of a patient’s mucus. Both these tests prevent an important expansion of the technologies available to those looking to combat the spread of the new coronavirus, since they can provide lab-quality results, but can do so much faster, and without requiring transportation of the samples from the point of collection to off-site testing facilities

More:

Mesa Biotech gains emergency FDA approval for rapid, point-of-care COVID-19 test

Leave a Reply

You must sign in to post a comment.